Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 25, 2025
Deals
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report
Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more
BioCentury | Feb 12, 2025
Discovery & Translation
Pain targets in ion channel pathways: an Innovation Distillery spotlight
Upstream regulators of ion channel expression or function are an emerging frontier for novel pain targets
BioCentury | Feb 11, 2025
Deals
After stumbles along winding path, Acelyrin merges with Alumis: Deals Report
Plus: Pair of cash-rich biotechs agree to combine, and Australian radiopharma company Advancell follows venture round by expanding Lilly relationship
BioCentury | Dec 18, 2024
Product Development
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report
Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | Dec 17, 2024
Product Development
Viridian taking on Amgen in TED market
Positive data from second Phase III trial of veligrotug in thyroid eye disease; this time in chronic setting
BioCentury | Dec 16, 2024
Distillery Therapeutics
Inhibiting FST-IGF1R interaction for neuropathic pain
BioCentury | Sep 12, 2024
Product Development
Clinical Report: AstraZeneca, Daiichi turn to precision medicine after OS miss for Dato-DXd
Plus: Results from Relay, Centessa, Viridian, Amgen and more
BioCentury | Aug 14, 2024
Product Development
Clinical Report: Acelyrin shifts priorities; Rivus moving forward in obesity
Plus: Readouts from Avidity, Apellis/Sobi, Levicept and Merck
BioCentury | May 9, 2024
Management Tracks
C-suite changes at Acelyrin could signal reprioritizations in pipeline
With CEO Shao-Lee Lin leaving, the company said it’s aiming to preserve cash resources, with a series of decision-driving clinical catalysts on the way
Items per page:
1 - 10 of 679